SIM-0613

N/A

Report date: 2026/05/07 20:00:36

Base Information

Drug NameSIM-0613
Drug Alias NameSIM-0613SIM0613
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-LRRC15
TargetsLeucine-rich repeat-containing protein 15
Therapy Area/IndicationsSolid tumoursNeoplasm Metastasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJiangsu Simcere Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesIpsen Pharma SasShanghai Xianwei Pharmaceutical Technology Co LtdJiangsu Simcere Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm Metastasis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A